Efficacy and Safety of TD-1473 in Crohn's Disease

A Phase 2 multi‐center, randomized, double blind, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of 12 weeks of induction therapy with TD˗1473 in subjects with moderately‐to‐severely active Crohn's Disease. This study includes 3 phases: Screening, Induction, and Active Treatment Extension (ATE). The Induction phase of the study is a randomized, double blind, placebo controlled, parallel group study evaluating 2 oral dose levels of TD‐1473 compared to placebo for 12 weeks in subjects with moderately to‐severely active CD. Subjects who complete Induction will continue to receive TD‐1473 in the ATE, for up to 48 additional weeks.